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Abstract The complement (C) system, a major component of
the innate immune system, has been described as a factor im-
plicated in some brain disorders. C activation leads to the re-
lease of anaphylatoxins, two proin£ammatory polypeptides act-
ing through speci¢c receptors that have been detected on brain
cells. Here, we examined the e¡ect of anaphylatoxins on chemo-
kine expression by human astrocytes. We showed that anaphy-
latoxins signi¢cantly increase chemokine mRNA expression.
However, anaphylatoxin-induced chemokine secretion (interleu-
kin-8) was observed only in the presence of interleukin-1L. Thus,
anaphylatoxins could initiate a chemokine cascade and, at least
in part, be involved in pathogenesis of the brain.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The complement (C) system is a key component of the
innate immune system playing a central role in host defence
against pathogens and in the initiation of in£ammation [1].
Within the brain, C has been suspected to be implicated in the
exacerbation of numerous human neurodegenerative disorders
including Alzheimer’s disease (AD) [2,3] and Pick’s disease
and demyelinating diseases such as multiple sclerosis (MS)
[4]. Indeed, studies have demonstrated the lethal e¡ects of C
on brain cells in vitro and in experimental models of MS by
lysing neurons and oligodendrocytes, respectively [5^7].
During in£ammation, C activation leads to the release of
various fragments including anaphylatoxins C3a and C5a lib-
erated by the cleavage of C3 and C5 by C convertases. These
potent proin£ammatory peptides share several biological ac-
tivities including mast cell degranulation, enhancement of vas-
odilatation, smooth muscle contraction and recruitment of
immune cells to the site of in£ammation [1]. They exert their
biological activities by binding to a speci¢c membrane recep-
tor coupled to G proteins named C3aR and C5aR, respec-
tively. Broadly distributed especially on myeloid cells, they
have been shown to induce the production of some cytokines
when stimulated [8,9]. In the central nervous system (CNS),
glial cells and neurons express the C3aR and C5aR receptors
[10,11] and our laboratory has contributed to the study of the
role of anaphylatoxins in the CNS, especially on astrocytes
[10^13]. We speculate that the C system may initiate, through
anaphylatoxin release, a chemokine cascade.
Chemokines represent a large family of small, basic, soluble
proteins that govern leukocyte transendothelial migration in a
gradient-dependent manner. They and their receptors are con-
sidered the principal factor that drives the composition of
in£ammatory in¢ltrates by attracting and activating leuko-
cytes. However, chemokines can inappropriately activate im-
mune cells leading to in£ammation and host cell destruction.
In the CNS, chemokines are induced in various human dis-
eases including AD [14], MS [15^17], human immunode¢-
ciency virus encephalitis [18], and bacterial meningitis [19],
and are thought to play an important role in pathogenesis.
The roles of anaphylatoxins on brain cells remain largely
unknown and in order to evaluate their actions in the CNS, in
the present study we studied the e¡ect of C3a and C5a on
chemokine expression by astrocytes. These new observations
may have important implications for understanding of dis-
eases and so far C3aR and C5aR could be considered new
therapeutic targets.
2. Materials and methods
2.1. Reagents, cytokines and antibodies
Pertussis toxin (PTX), human recombinant C5a and interleukin
(IL)-1L were purchased from Sigma (St Quentin Fallavier, France).
Anti-C3a monoclonal antibody (G10) and anti-C5aR polyclonal anti-
body, used to block the e¡ect of C3a and C5aR, respectively, were
characterized previously [13,20]. Human C3a was generated by acti-
vation of C and puri¢ed as previously described [13]. Multiple-asso-
ciated-peptide (MAP)-C3a and MAP-C5a peptides corresponding to
the C-terminal part of the anaphylatoxins (amino acids correspond to
64^77 for C3a and 61^74 for C5a) attached to a poly-lysine comb
(eight peptide monomers) were synthesized by solid phase synthesis
(Applied Biosystems) and were puri¢ed by reverse phase high perfor-
mance liquid chromatography. Sequences were ascertained by amino
acid analysis.
2.2. Cell culture
The human glioblastoma cell line T98G was obtained from the
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American Type Culture Collection (Rockville, MD, USA). These cells
were screened routinely by the Mycoplasma Detection Kit (Boehr-
inger Mannheim, Meylan, France) to ensure that they were mycoplas-
ma-free. Cells were grown in Ham’s F12 culture medium (Biowhit-
taker, Emerainville, France) supplemented with 1% penicillin and
streptomycin (Life Technologies, Cergy-Pontoise, France), and 10%
heat-inactivated fetal calf serum (Life Technologies). Primary cultures
of human fetal astrocytes were established from fetal brain (18-week-
old fetus) as previously described [12]. The astrocyte marker glial
¢brillary acidic protein was detected by £ow cytometry in 95^97%
of total cells. Experiments were conducted on cell cultures from the
¢rst to the third passage.
2.3. RNA extraction
Total RNAs were extracted from cells by the guanidinium isothio-
cyanate method followed by ultracentrifugation onto a cesium chlo-
ride cushion as described by Sambrook et al. [21]. Total RNAs (50 Wg)
were treated for 20 min at 37‡C with 90 U of RQ-1 RNase-free
DNase (Promega, Charbonnie'res, France) in 100 Wl of bu¡er (40
mM Tris^HCl pH 8, 10 mM NaCl, 6 mM MgCl2, 10 mM CaCl2)
and 200 U of RNasin ribonuclease inhibitor (Promega) to remove all
traces of contaminating genomic DNA.
2.4. PCR primers
Human IL-8 and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) primers were chosen according to their cDNA sequences
reported in the EMBL data library under accession numbers
XM031289 and M33197. Their sequences from 5P to 3P are: IL-8
(sense): TCT TGG CAG CCT TCC TGA TT; IL-8 (antisense):
AAC TTC TCC ACA ACC CTC TG; GAPDH (sense): TGC CAT
CAA CGA CCC CTT CA; GAPDH (antisense): TGA CCT TGC
CCA CAG CCT TG. The theoretical size was 249 bp for IL-8 and
549 bp for GAPDH.
2.5. RT-PCR
Semi-quantitative RT-PCR was carried out with a GAPDH:IL-8
primer ratio of 1:75 and 1 WCi [33P]dATP (Redivue, Amersham, Les
Ulis, France) [20]. Experiments were conducted in which RNA bands
after ampli¢cation were detected within the linear part of the amplify-
ing curves so that plateau phases were not reached. Autoradiograms
were analyzed by scanning using a Lecphor image analyzer (Biocom,
Les Ulis, France). Results are expressed as the ratio of the area of the
band of IL-8 to the mean of the area of the housekeeping gene band.
The IL-8 mRNA value, from unstimulated cells, was arbitrarily set at
one unit and values for the other samples were calculated relative to
it.
2.6. Ribonuclease protection assay (RPA)
After total RNA extraction, RPA was performed using the Ribo-
Quant Multiprobe RNase Protection Assay System (BD Pharmingen,
Le Pont de Claix, France), according to the manufacturer’s instruc-
tions. Brie£y, the provided human chemokine template set (hCK-5)
contained probes for eight chemokines: lymphotactin (Ltn), regulated
on activation, normal T cells expressed and secreted (RANTES), in-
terferon-Q-inducible protein of 10 kDa (IP-10), macrophage in£amma-
tory protein 1K and 1L (MIP-1K, MIP-1L), monocyte chemoattractant
protein (MCP-1), IL-8, and I-309, and two housekeeping genes
(GAPDH and L-32). To synthesize antisense cRNA, the probes
were labeled with [32P]KUTP (800 Ci/mmol, 10 mCi/ml; Amersham)
using a transcription kit according to the manufacturer’s manual. Ten
micrograms of each sample was used for hybridization with the anti-
sense RNA probe at 56‡C for 12^16 h, followed by digestion of free
probe and unprotected single-stranded RNA with RNase solution
(RNase A plus RNase T1). The remaining double-stranded RNA
was then extracted in chloroform/isoamyl alcohol (50:1) and was pre-
cipitated with ethanol and separated on a 7 M urea/6% polyacryl-
amide gel. A part of the undigested probe was used as a marker
standard. After drying, the gel was placed in the exposure cassette
with a phosphor screen for 48 h. Bands were detected by phosphor-
imaging using ImageQuant software (Molecular Dynamics). A stan-
dard curve plotted with the undigested probe markers was used to
identify the bands of various genes in the experimental samples. Re-
sults were expressed as the ratio of the volume of the band of interest
to the mean of the volumes of the bands for the housekeeping genes.
The chemokine mRNA value, from unstimulated cells, was arbitrarily
set at one unit and values for the other samples were calculated rel-
ative to it.
2.7. Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IL-8 protein in culture supernatant samples were
determined by a speci¢c sensitive ELISA as previously described [22].
The absorbance was measured at A492nm with a plate reader (Labsys-
tems iEMS Reader MF) and IL-8 concentration in the samples was
determined by comparison with an IL-8 standard curve. The level of
IL-8 in the culture supernatants was expressed as pg/ml per 106 cells.
2.8. Statistical analysis
Data are expressed as the meanSS.E.M. Statistical analysis was
performed using Student’s t-test. Di¡erences were considered statisti-
cally signi¢cant at P6 0.05.
3. Results
3.1. C3a and C5a anaphylatoxins enhanced chemokine mRNA
expression on human glioblastoma cells
In a ¢rst approach, we studied chemokine mRNA expres-
sion on the human glioblastoma cell line T98G. This cell line
expressed C3a and C5a receptors [12,23] and responded to
anaphylatoxin stimulation [20].
T98G cells were stimulated by MAP-C3a or MAP-C5a
(1038 M), two strong peptide anaphylatoxin analogues, and
total RNAs were extracted after di¡erent stimulation times (2,
4, 6, 12 and 24 h). The variation of chemokine mRNA ex-
pression was analyzed by the sensitive RPA technique. Thus,
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Fig. 1. Expression of chemokines by T98G cells stimulated by
MAP-C3a or MAP-C5a (1038 M). T98G cells were stimulated for
2, 4, 6, 12 or 24 h by MAP peptides and chemokine mRNA expres-
sion was determined by RPA. A representative blot is shown in the
top panel and the matching ratios expressed as relative fold increase
over control are represented in the bottom panel. Lane M repre-
sents the multi-probe template set not treated with RNases which
serves as a ladder. NS=non-stimulated cells.
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at the same time, we studied Ltn, RANTES, IP-10, MIP-1K,
MIP-1L, IL-8 and I-309 mRNA expression using GAPDH
and L-32 as internal standards. Results are presented as rela-
tive fold increase over control (unstimulated cells). We ob-
served that unstimulated T98G cells constitutively express
low levels of MCP-1 and IL-8 mRNA (Fig. 1, top).
Stimulation of T98G cells induced a high increase of MCP-1
mRNA expression which was increased 10.5-fold and 6.0-fold
after 4 h stimulation with MAP-C3a and MAP-C5a, respec-
tively (Fig. 1, bottom). The IL-8 mRNA level was also in-
creased 9.4-fold after 4 h of stimulation by MAP-C3a and 11-
fold after 2 h of stimulation by MAP-C5a. We also detected a
weak induction of IP-10 mRNA expression, especially after
MAP-C5a stimulation. However, MAP peptide stimulation
did not induce Ltn, RANTES, MIP-1K, MIP-1L or I-309
mRNA on T98G cells.
The upregulation of IL-8 mRNA expression induced by
MAP-C3a and MAP-C5a was also observed when using hu-
man puri¢ed C3a and recombinant C5a. T98G cells were
stimulated with C3a or C5a (1038 M) and IL-8 mRNA ex-
pression was studied by semi-quantitative RT-PCR. After 4 h
of stimulation, the IL-8 mRNA level was increased by 5.3-fold
and 6.2-fold, respectively (Fig. 2).
3.2. Anaphylatoxin-upregulated IL-8 mRNA expression was
speci¢c and dose-dependent
In order to ascertain the speci¢city of anaphylatoxins in the
upregulation of IL-8 mRNA, we tried to block their e¡ect by
speci¢c antibodies. Pre-incubation of C3a anaphylatoxin with
an anti-C3a monoclonal antibody (1/100) for 30 min com-
pletely blocked the upregulation of IL-8 gene expression in-
duced by C3a alone (Fig. 2). Similarly, when cells were pre-
incubated for 30 min with an anti-C5aR polyclonal antibody
(1/100) before C5a stimulation, the C5a-induced IL-8 mRNA
upregulation was abolished (Fig. 2).
C3a and C5a anaphylatoxins are known to bind to their
own receptors, which are functionally coupled to G proteins
[24,25]. To con¢rm that anaphylatoxin stimulation leading to
the upregulation of IL-8 mRNA acted through a G protein-
coupled pathway, T98G cells were pre-incubated with PTX
(200 ng/ml) for 4 h before application of MAP peptides. After
4 h of stimulation by anaphylatoxin agonists or without stim-
ulation, the level of IL-8 mRNA was determined. PTX alone
had no e¡ect on IL-8 expression but pre-treatment of cells by
PTX completely abrogated the upregulation of IL-8 mRNA
expression induced by anaphylatoxin agonists (Fig. 3).
T98G cells were stimulated with increasing concentrations
of MAP peptides or anaphylatoxins in a concentration range
of 10313^1037 M. Total RNAs were extracted after 4 h of
stimulation and IL-8 mRNA expression was measured.
From 10310 to 1038 M, we observed a linear relationship
between IL-8 mRNA expression and the concentration of
di¡erent peptides showing a dose-dependent increase of IL-8
mRNA (data not shown).
3.3. C3a and C5a anaphylatoxins enhanced chemokine mRNA
expression on human fetal astrocytes
To con¢rm previous results obtained with the T98G cell
line, we examined chemokine expression on human primary
astrocytes stimulated by MAP-C3a or MAP-C5a (1038 M).
The variation of chemokine mRNA expression after di¡erent
stimulation times (2, 4, 6, 12 and 24 h) was carried out using
the RPA technique. Results representing relative fold increase
over control (unstimulated cells) are shown in Fig. 4.
Thus, we observed that human fetal astrocytes constitu-
tively expressed low level of RANTES, IP-10, MCP-1 and
IL-8 but not Ltn, MIP-1K, MIP-1L or I-309 mRNA. Stimu-
lation of astrocytes by MAP peptides increased the RANTES,
IP-10 and MCP-1 mRNA expression two-fold at most. As for
glioblastoma cells, IL-8 mRNA expression exhibited the
greatest increase after 4 h of peptide stimulation. We also
detected an induction of MIP-1K mRNA expression.
3.4. C3a and C5a stimulation increased IL-8 release by T98G
cells
As IL-8 mRNA expression showed the higher increase in
response to anaphylatoxin stimulation, we wanted to study
IL-8 secretion by astrocytic cells stimulated with anaphylatox-
ins. The supernatants of stimulated T98G cells were collected
after 12, 24, 48 and 72 h stimulation by either MAP peptides
Fig. 2. Expression of IL-8 mRNA after stimulation of T98G cells
by C3a or C5a anaphylatoxins (1038 M). E¡ect of pre-incubation
with anti-C3a or anti-C5aR antibodies. C3a anaphylatoxin was pre-
incubated for 30 min with an anti-C3a antibody (diluted 1/100), or
cells were pre-incubated for 30 min with an anti-C5aR antibody (di-
luted 1/100) before 4 h stimulation by C3a or C5a (1038 M), respec-
tively. Total RNAs were extracted and RT-PCR was performed.
Bars represent the meanSS.E.M. of triplicate samples. A represen-
tative graph of n=3 independent experiments is shown. *P6 0.05,
statistically signi¢cant di¡erence compared with non-stimulated cells
(NS) as determined by Student’s t-test; #P6 0.05, statistically signif-
icant di¡erence compared with cells stimulated with C5a as deter-
mined by Student’s t-test; n.d., not determined.
* *
# #
Fig. 3. In£uence of PTX on the IL-8 mRNA production by T98G
cells following stimulation with MAP-C3a or MAP-C5a (1038 M).
Cells were pre-incubated for 4 h with PTX (200 ng/ml) and then
stimulated by MAP-C3a or MAP-C5a for 4 h. Cells were also incu-
bated with PTX alone. Total RNAs were extracted and RT-PCR
was performed. Bars represent the meanSS.E.M. of triplicate sam-
ples. A representative graph of n=3 independent experiments is
shown. *P6 0.05, statistically signi¢cant di¡erence compared with
non-stimulated cells (NS) as determined by Student’s t-test;
#P6 0.05, statistically signi¢cant di¡erence compared with cells
stimulated with MAP peptides as determined by Student’s t-test.
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or anaphylatoxins (1038 M) and the concentration of IL-8
protein was analyzed by speci¢c sensitive ELISA. The release
of IL-8 is time-dependent in response to C3a/C5a and was
maximal after 48 h of stimulation (data not shown). The con-
centration of IL-8 was then analyzed by speci¢c ELISA. The
results are presented in Fig. 5.
A basal level of IL-8 produced by T98G cells was detected
(54S 16 pg/ml/106 cells) and a weak increase of the IL-8
amount in the supernatant was observed after MAP peptide
stimulation. After 48 h of stimulation, the IL-8 amount
reached 144S 32 pg/ml/106 cells for MAP-C3a and 83S 24
pg/ml/106 cells for MAP-C5a. No signi¢cant increase of IL-8
secretion was observed after anaphylatoxin stimulation.
As anaphylatoxins are generated in an in£ammatory con-
text where other cytokines, including IL-1L, are also released,
we wanted to investigate the e¡ect of anaphylatoxin/IL-1L co-
stimulation on IL-8 release. First, we measured the release of
IL-8 in the supernatant of T98G cells after 48 h of stimulation
by increasing concentrations of IL-1L in order to determine
the sub-optimal dose of IL-1L which did not increase the IL-8
secretion rate (Fig. 6A).
No increase of IL-8 secretion was observed for concentra-
tions of IL-1L below 0.05 U/ml. Then, we co-stimulated T98G
cells for 48 h with IL-1L (0.03 U/ml) and with C3a, C5a,
MAP-C3a or MAP-C5a (1038 M) (Fig. 6B). We observed
that when T98G cells were co-stimulated by anaphylatoxins
(1038 M) and IL-1L (0.03 U/ml), the IL-8 release was highly
increased compared to that after stimulation by anaphylatox-
ins alone. Thus, IL-8 secretion reached 239S 57 pg/ml/106
cells for IL-1L 0.03 U/ml+C3a, 300S 61 pg/ml/106 cells for
IL-1L 0.03 U/ml+C5a, 478S 69 pg/ml/106 cells for IL-1L
0.03 U/ml+MAP-C3a and 383S 69 pg/ml/106 cells for IL-1L
0.03 U/ml+MAP-C5a showing a synergistic e¡ect of anaphy-
latoxins and IL-1L on the secretion by astrocyte cells.
β
α
α
Fig. 4. Expression of chemokines by fetal astrocytes stimulated by MAP-C3a or MAP-C5a (1038 M). A representative autoradiogram of che-
mokine mRNA expression by fetal astrocytes after 2, 4, 6, 12 or 24 h of stimulation by MAP peptides is shown in the top panel. See legend of
the Fig. 1.
Fig. 5. Production of IL-8 by T98G cells by ELISA after incubation
with C3a, C5a, MAP-C3a or MAP-C5a (1038 M) for 48 h. The
concentration of IL-8 was measured in the supernatants and is ex-
pressed as pg/ml per 106 cells. Bars represent the meanSS.E.M. of
triplicate samples. A representative graph of n=3 independent ex-
periments is shown.
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4. Discussion
The C system plays an important role in the control of
infection by lysis and opsonization of microorganisms and
in the initiation and the control of in£ammation. C3a and
C5a anaphylatoxins, generated during C activation by the
proteolytic cleavage of C3 and C5 components, are two strong
in£ammatory polypeptides. C5a and to a lesser extent C3a are
important chemoattractant molecules that have the capacity
to modulate synthesis of cytokines such as IL-1L, tumor ne-
crosis factor K (TNF-K), IL-6 and IL-8 by myeloid cells
[8,9,26^29]. Anaphylatoxins regulate in£ammatory functions
by interacting with their own receptors, C3aR and C5aR,
coupled to PTX-sensitive G protein [30^33]. Traditionally,
C3aR and C5aR were thought to be present only on myeloid
cells. However, further studies have demonstrated these recep-
tors on non-myeloid cells and both receptors have been de-
tected on neurons and glial cells of the CNS [10^12,23]. In-
terestingly, our laboratory has shown that astrocytes
stimulated with anaphylatoxins produced increased levels of
IL-6 mRNA while the levels of IL-1L, TNF-K and transform-
ing growth factor-L remained una¡ected [20]. The properties
of anaphylatoxins in the CNS remain largely unknown and to
obtain further clues on their actions, we examined the release
of chemokines by astrocytes upon stimulation with anaphyla-
toxins using the sensitive RPA technique. The chemokines
examined were RANTES, MIP-1K, MIP-1L, MCP-1 and
I-309, belonging to the CC chemokine family, and IP-10
and IL-8, two CXC chemokines.
First, we investigated chemokine mRNA expression in re-
sponse to anaphylatoxins on the human T98G cell. We ob-
served that this cell line expressed constitutively low levels of
MCP-1 and IL-8 mRNA and we showed an increased expres-
sion of them and an induction of IP-10 mRNA expression
after stimulation by anaphylatoxins. The anaphylatoxin-in-
duced IL-8 release has been shown to be dose-dependent since
IL-8 mRNA expression varied with the concentration of ana-
phylatoxins and to act through a G protein-coupled pathway
since pre-treatment of cells with PTX completely blocked the
IL-8 response. Furthermore, pre-incubation with anti-C3a or
anti-C5aR antibodies abolished the C3a- and C5a-induced
IL-8 mRNA increase respectively, showing that the response
was speci¢c.
Chemokine mRNA expression was also studied on fetal
human primary astrocytes stimulated by anaphylatoxins. Un-
stimulated cells expressed low levels of RANTES, IP-10,
MCP-1 and IL-8 mRNA which increased after anaphylatoxin
stimulation. We also observed an induction of MIP-1K
mRNA. Astrocytes have already been shown to respond to
several proin£ammatory cytokines such as IL-1L, TNF-K or
interferon-Q to induce some chemokine expression [34]. Thus,
anaphylatoxins, released during C activation, could be anoth-
er stimulus that leads to chemokine upregulation in the CNS.
Then, we investigated IL-8 secretion by T98G cells in re-
sponse to anaphylatoxins. Cells were stimulated for 48 h with
C3a, C5a or MAP peptides and the concentration of IL-8 was
determined in the supernatant by speci¢c ELISA assay. Thus,
compared to unstimulated cells, we observed a weak increase
of IL-8 secretion only after stimulation by MAP peptides.
This phenomenon of transcription activity without protein
synthesis has already been observed by several groups in dif-
ferent cell types. Peripheral blood mononuclear cells stimu-
lated by C5a anaphylatoxin have shown signi¢cant levels of
IL-1L mRNA without the appearance of a proportional
amount of IL-1L protein [27,35,36]. Our laboratory has also
observed a high increase of IL-6 mRNA expression by astro-
cytes after anaphylatoxin stimulation without detecting any
protein [20]. As anaphylatoxins are generated in an in£amma-
tory context where cytokines are also released, we investigated
the e¡ect of anaphylatoxin/IL-1L co-stimulation on IL-8 re-
lease. We showed here an e¡ect of a sub-optimal dose of IL-
1L on the anaphylatoxin-induced IL-8 release. Thus, even if
anaphylatoxins alone are unable to enhance chemokine secre-
tion by astrocytes, they could when co-stimulated with pro-
in£ammatory cytokines such as IL-1L. As the C system could
be inappropriately activated leading to the promotion of seri-
ous damage in the CNS, this mechanism may constitute a
protection against inappropriate activation of the C system
and stop the in£ammatory cascade. Thus, anaphylatoxins
could play an important role in priming astrocytes during
in£ammatory responses in the brain.
Our results demonstrated several homogeneous and speci¢c
patterns of chemokine gene expression by human astrocytes
in response to anaphylatoxins. Chemokines seem to play a
crucial role in neuroin£ammation where most diseases are
accompanied by chemokine expression, including MCP-1,
MCP-2, MIP-1K, MIP-1L, RANTES, IL-8 and IP-10
[37,38]. Several studies have demonstrated the expression of
Fig. 6. E¡ect of anaphylatoxin/IL-1L co-stimulation on IL-8 release
by T98G cell line. First, cells were stimulated for 48 h by increasing
doses of IL-1L to determine the maximal concentration of IL-1L
which did not induce IL-8 release (A). Second, cells were co-stimu-
lated for 48 h with a sub-optimal dose of IL-1L (0.03 U/ml) with
C3a, C5a, MAP-C3a or MAP-C5a (1038 M) (B). The concentration
of IL-8 was measured in the supernatants by ELISA and is ex-
pressed as pg/ml per 106 cells. Bars represent the meanSS.E.M. of
triplicate samples. A representative graph of n=3 independent ex-
periments is shown. #P6 0.05, statistically signi¢cant increase com-
pared with cells stimulated with IL-1L 0.03 U/ml as determined by
Student’s t-test.
FEBS 26975 13-2-03
A.-C. Jauneau et al./FEBS Letters 537 (2003) 17^22 21
chemokines and especially IP-10 and RANTES in the CNS
tissue of MS [17,39^43]. Because they are potent T-cell che-
moattractants, their elevated levels during active episodes of
MS may induce migration of T-cells into the brain. During
AD, it is suggested that chemokine expression may also con-
tribute to the development and/or the progression of the dis-
ease [14].
The role of chemokines in control of CNS bacterial infec-
tions is not well understood. However, it has been demon-
strated that patients with bacterial meningitis show chemokine
expression in the cerebrospinal £uid [44]. Furthermore, when
mouse brains were infected by Staphylococcus aureus, chemo-
kines were expressed locally [45]. These examples point out
the involvement of chemokines in host defence against bacte-
rial infections of the CNS.
Our data show that stimulation of human astrocytes by
anaphylatoxins could lead to chemokine mRNA upregulation
or induction and to possible chemokine secretion (IL-8) but
only when co-stimulated with IL-1L. The most general re-
sponse to chemokine stimulation is chemotaxis of di¡erent
types of leukocytes. Thus, chemokine upregulation by astro-
cytes in response to C3a and C5a anaphylatoxins may have
important implications during brain in£ammatory diseases.
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